Citron Updates Arthrocare
| stock ticker: ARTC | ||
 |
      |
|
“If you rely on analysts for the prognosis, investors had better to seek a second opinion”
After the sharp downturn in Arthrocare last week, its analyst/cheerleader decided to keep their head in the sand and defend the company with the blanket logic on the theme of “management disagrees with a short seller”. The most interesting of all the defenses was that of Piper Jaffray who not only attempted to discredit Citron but also went on in saying that their internal research did not have the company using or suggesting any improper codes. Time to do more research.